Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation

• Published in: Blood Vol. 123; no. 23; pp. 3664 - 3671
• Main Authors: Armand, Philippe, Kim, Haesook T., Logan, Brent R., Wang, Zhiwei, Alyea, Edwin P., Kalaycio, Matt E., Maziarz, Richard T., Antin, Joseph H., Soiffer, Robert J., Weisdorf, Daniel J., Rizzo, J. Douglas, Horowitz, Mary M., Saber, Wael
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 05.06.2014; American Society of Hematology
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Female; Health Status Indicators; Hematologic Neoplasms - mortality; Hematologic Neoplasms - therapy; Hematopoietic Stem Cell Transplantation - adverse effects; Hematopoietic Stem Cell Transplantation - mortality; Humans; Male; Middle Aged; Risk Assessment; Transplantation; Transplantation Conditioning - mortality; Transplantation, Homologous - adverse effects; Young Adult
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2014-01-552984

Because the outcome of allogeneic hematopoietic cell transplantation (HCT) is predominantly influenced by disease type and status, it is essential to be able to stratify patients undergoing HCT by disease risk. The Disease Risk Index (DRI) was developed for this purpose. In this study, we analyzed 13 131 patients reported to the Center for International Blood and Marrow Transplant Research who underwent HCT between 2008 and 2010. The DRI stratified patients into 4 groups with 2-year overall survival (OS) ranging from 64% to 24% and was the strongest prognostic factor, regardless of age, conditioning intensity, graft source, or donor type. A randomly selected training subgroup of 9849 patients was used to refine the DRI, using a multivariable regression model for OS. This refined DRI had improved prediction ability for the remaining 3282 patients compared with the original DRI or other existing schemes. This validated and refined DRI can be used as a 4- or 3-group index, depending on the size of the cohort under study, for prognostication; to facilitate the interpretation of single-center, multicenter, or registry studies; to adjust center outcome data; and to stratify patients entering clinical trials that enroll patients across disease categories. •The DRI successfully stratified patients in a very large allogeneic transplantation registry cohort.•The DRI was refined by using this cohort to build a more inclusive and conditioning intensity–independent index.